SLIRP Activators
SLIRP Activators are a collection of chemical entities that augment the functional activity of SLIRP via various indirect cellular mechanisms, focusing on the modulation of cyclic AMP (cAMP) signaling and subsequent protein kinase A (PKA) activation. Forskolin, by elevating intracellular levels of cAMP, indirectly enhances SLIRP's functional role by activating PKA, which can phosphorylate substrates that interact with SLIRP, modifying its activity. Similar in their mechanism of action, 8-Bromoadenosine 3',5'-cyclic monophosphate and Sildenafil prevent the degradation of cAMP, leading to sustained PKA activation, which then might facilitate the phosphorylation of proteins associated with SLIRP's functional processes.
In addition to these cAMP-centric activators, compounds like Epigallocatechin Gallate (EGCG) and Resveratrol exert their influence on SLIRP activity through different pathways. EGCG, through its polyphenolic structure, might inhibit negative regulators of SLIRP or alter mitochondrial dynamics, which is closely linked to SLIRP's function. Resveratrol, by activating sirtuins, supports mitochondrial function and thus could indirectly enhance SLIRP activity by optimizing the environment where SLIRP operates. Pioglitazone, a PPAR-gamma agonist, promotes mitochondrial biogenesis, raising SLIRP activity by increasing mitochondrial count, while Cilostamide and Zaprinast, as phosphodiesterase inhibitors, raise cAMP levels, further propagating PKA activity and amplifying SLIRP activity through protein phosphorylation within mitochondrial pathways. Collectively, these SLIRP Activators, by targeting different aspects of cellular signaling, facilitate the indirect enhancement of SLIRP's function without necessitating a direct interaction with the protein itself.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing the levels of cAMP in the cell. Elevated cAMP activates PKA, which can then phosphorylate various targets, potentially enhancing the activity of SLIRP by phosphorylating proteins that interact with SLIRP. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cell-permeable cAMP analog that activates PKA. PKA activation can lead to phosphorylation events that might enhance SLIRP activity by modifying its interaction with mitochondrial RNA. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, leading to increased cAMP and cGMP in the cell. The resultant activation of PKA can enhance SLIRP activity by phosphorylation of proteins in the SLIRP pathway. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective phosphodiesterase 4 inhibitor which elevates intracellular cAMP levels, potentially enhancing PKA activity and thereby increasing SLIRP activity through phosphorylation of SLIRP-associated proteins. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that can modulate various signaling pathways. It may enhance SLIRP activity by inhibiting proteins that negatively regulate SLIRP's function or by altering mitochondrial dynamics, which can affect SLIRP function. | ||||||
ZM 241385 | 139180-30-6 | sc-361421 sc-361421A | 5 mg 25 mg | $92.00 $356.00 | 1 | |
ZM 241385 is an adenosine A2A receptor antagonist, which may enhance SLIRP activity by altering signaling pathways that involve cAMP, thus potentially affecting PKA activity and SLIRP function indirectly. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol activates sirtuins, which are implicated in mitochondrial function. Activation of sirtuins could enhance SLIRP activity by improving mitochondrial function and thus indirectly affecting the pathways SLIRP is involved in. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone is a PPAR-gamma agonist, which can influence mitochondrial biogenesis and function, potentially enhancing SLIRP activity by increasing the number of mitochondria where SLIRP acts. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
db-cAMP is a cAMP analog that activates PKA. Increased PKA activity can lead to phosphorylation events that enhance SLIRP function by modifying the proteins that SLIRP interacts with in the mitochondria. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective inhibitor of phosphodiesterase 3, which increases cAMP levels. Higher cAMP may enhance PKA activity, potentially leading to increased SLIRP activity through phosphorylation of associated proteins. | ||||||